https://findrochetrials.ca2026-01-14https://findrochetrials.ca/en/trials.html2025-06-11https://findrochetrials.ca/en/trials/uncategorized.html2020-08-25https://findrochetrials.ca/en/trials/cancer/bc/a-study-evaluating-safety--pharmacokinetics--and-therapeutic-act.html2024-08-31https://findrochetrials.ca/en/trials/cancer/bc/a-study-of-ipatasertib-in-combination-with-paclitaxel-as-a-treat.html2024-08-31https://findrochetrials.ca/en/trials/cancer/bc/to-evaluate-the-safety--tolerability--and-pharmacokinetics-of-gd.html2025-03-19https://findrochetrials.ca/en/trials/cancer/bc/a-study-to-investigate-atezolizumab-and-chemotherapy-compared-wi.html2024-08-30https://findrochetrials.ca/en/trials/cancer/bc/a-phase-ii-study-comparing-the-efficacy-of-venetoclax---fulvestr.html2024-08-31https://findrochetrials.ca/en/trials/cancer/bc/a-study-to-evaluate-the-efficacy-and-safety-of-atezoliz-39916.html2024-11-06https://findrochetrials.ca/en/trials/cancer/bc/a-study-to-evaluate-the-efficacy-and-safety-of-trastuzu-87572.html2026-03-25https://findrochetrials.ca/en/trials/cancer/bc/a-study-of-trastuzumab-emtansine-versus-trastuzumab-as-adjuvant-.html2025-03-27https://findrochetrials.ca/en/trials/cancer/bc/a-study-of-ipatasertib-plus-palbociclib-and-fulvestrant-28505.html2024-11-09https://findrochetrials.ca/en/trials/cancer/bc/a-study-evaluating-the-efficacy-and-safety-of-gdc-0077--75564.html2025-03-27https://findrochetrials.ca/en/trials/cancer/bc/a-study-of-trastuzumab-emtansine--kadcyla--plus-pertuzu-91245.html2024-08-31https://findrochetrials.ca/en/trials/cancer/bc/a-study-of-pertuzumab-in-combination-with-trastuzumab---50542.html2024-08-31https://findrochetrials.ca/en/trials/cancer/bc/a-study-evaluating-the-efficacy-and-safety-of-gdc-9545--28702.html2025-03-27https://findrochetrials.ca/en/trials/cancer/bc/the-purpose-of-this-study-is-to-evaluate-the-efficacy-a-74702.html2025-03-27https://findrochetrials.ca/en/trials/cancer/bc/a-study-to-evaluate-efficacy-and-safety-of-giredestrant-50902.html2025-03-27https://findrochetrials.ca/en/trials/cancer/leukemia/a-study-of-dcll9718s-in-participants-with-relapsed-or-refractory.html2024-06-22https://findrochetrials.ca/en/trials/cancer/leukemia/a-study-of-idasanutlin-with-cytarabine-versus-cytarabine-plus-pl.html2024-06-22https://findrochetrials.ca/en/trials/cancer/leukemia/a-study-to-compare-the-efficacy-and-safety-of-obinutuzu-46860.html2025-03-27https://findrochetrials.ca/en/trials/cancer/oc.html2023-05-10https://findrochetrials.ca/en/trials/cancer/cca/a-study-of-tiragolumab-plus-atezolizumab-and-atezolizum-32500.html2025-03-27https://findrochetrials.ca/en/trials/cancer/pv/a-study-to-evaluate-the-efficacy--safety--pharmacokinetics-and-p.html2024-08-30https://findrochetrials.ca/en/trials/cancer/a-study-in-participants-previously-enrolled-in-a-genentech-and-o.html2025-02-07https://findrochetrials.ca/en/trials/cancer/bladder-cancer/a-study-of-moxr0916-in-combination-with-atezolizumab-versus-atez.html2024-08-31https://findrochetrials.ca/en/trials/cancer/bladder-cancer/study-of-atezolizumab-as-monotherapy-and-in-combination-with-pla.html2025-02-25https://findrochetrials.ca/en/trials/cancer/lung-cancer/a-study-of-atezolizumab-compared-with-chemotherapy-in-treatment-.html2024-10-24https://findrochetrials.ca/en/trials/cancer/lung-cancer/a-study-to-evaluate-efficacy-and-safety-of-multiple-targeted-the.html2025-03-27https://findrochetrials.ca/en/trials/cancer/lung-cancer/a-study-comparing-alectinib-with-crizotinib-in-treatmen-47622.html2025-03-27https://findrochetrials.ca/en/trials/cancer/lung-cancer/a-study-of-atezolizumab-and-tiragolumab-compared-with-d-48756.html2025-03-27https://findrochetrials.ca/en/trials/cancer/lung-cancer/a-study-of-tiragolumab-in-combination-with-atezolizumab-98469.html2025-03-27https://findrochetrials.ca/en/trials/cancer/multiple-myeloma/dose-escalation-study-of-bfcr4350a-in-participants-with-relapsed.html2025-02-25https://findrochetrials.ca/en/trials/cancer/rcc/a-study-of-atezolizumab-plus-bevacizumab-versus-active--52983.html2025-03-27https://findrochetrials.ca/en/trials/cancer/skin-cancer/a-phase-ib-study-to-evaluate-safety-and-therapeutic-act-73518.html2024-10-04https://findrochetrials.ca/en/trials/cancer/skin-cancer/a-study-comparing-vemurafenib-versus-vemurafenib-plus-c-99807.html2024-06-21https://findrochetrials.ca/en/trials/cancer/hepatocellular-carcinoma/a-study-of-atezolizumab-in-combination-with-bevacizumab-compared.html2024-09-01https://findrochetrials.ca/en/trials/cancer/Head_and_Neck_Cancer/a-study-of-atezolizumab--antipd-l1-antibody--as-adjuvant-therapy.html2024-10-10https://findrochetrials.ca/en/trials/cancer/Brain_Tumor.html2020-08-25https://findrochetrials.ca/en/trials/cancer/pancreatic-cancer.html2020-08-25https://findrochetrials.ca/en/trials/cancer/pancreatic-cancer/a-study-of-multiple-immunotherapy-based-treatment-combinations-i2.htmlhttps://findrochetrials.ca/en/trials/cancer/an-extension--rollover--study-of-vemurafenib-in-participants-wit.html2024-08-30https://findrochetrials.ca/en/trials/cancer/safety-and-pharmacokinetics--pk--of-escalating-doses-of-mtig7192.html2024-12-06https://findrochetrials.ca/en/trials/cancer/prostate-cancer/ipatasertib-plus-abiraterone-plus-prednisone-prednisolone--relat.html2024-08-31https://findrochetrials.ca/en/trials/cancer/gc.html2020-08-25https://findrochetrials.ca/en/trials/cancer/a-study-of-atezolizumab-in-locally-advanced-or-metastat-72736.html2024-08-31https://findrochetrials.ca/en/trials/cancer/an-extension-study-to-provide-continued-bevacizumab-therapy-to-p.html2024-08-30https://findrochetrials.ca/en/trials/cancer/fmi.html2023-05-10https://findrochetrials.ca/en/trials/cancer/non-hodgkins-lymphoma/a-study-to-evaluate-the-safety-and-efficacy-of-mosunetu-47106.html2024-06-21https://findrochetrials.ca/en/trials/cancer/non-hodgkins-lymphoma/a-dose-escalation-study-of-ro7082859-as-a-single-agent-and-in-co.html2025-03-13https://findrochetrials.ca/en/trials/cancer/non-hodgkins-lymphoma/a-study-evaluating-the-safety--efficacy-and-pharmacokin-79640.html2024-09-01https://findrochetrials.ca/en/trials/cancer/a-study-of-the-safety--pharmacokinetics--and-therapeuti-98047.html2024-08-31https://findrochetrials.ca/en/trials/cancer/endometrial-cancer.html2023-05-10https://findrochetrials.ca/en/trials/cancer/solid-tumors/an-open-label-dose-escalation-study-to-evaluate-xmab243-88679.html2025-01-28https://findrochetrials.ca/en/trials/cancer/solid-tumors/a-study-to-evaluate-the-safety--tolerability--pharmacok-12037.html2024-08-31https://findrochetrials.ca/en/trials/cancer/solid-tumors/a-study-to-evaluate-the-safety-and-tolerability-of-ro72-99201.html2024-08-30https://findrochetrials.ca/en/trials/cancer/solid-tumors/tumor-agnostic-precision-immuno-oncology-and-somatic-ta-50851.html2025-03-27https://findrochetrials.ca/en/trials/cancer/solid-tumors/a-study-to-evaluate-the-safety-and-tolerability-of-ro72-03496.htmlhttps://findrochetrials.ca/en/trials/cancer/solid-tumors/screening-study-for-participants-with-malignant-tumors-95723.html2025-03-27https://findrochetrials.ca/en/trials/cancer/thymic-carcinoma.html2020-08-25https://findrochetrials.ca/en/trials/cancer/a-study-to-assess-safety-and-pharmacokinetics-of-moxr09-56953.html2024-08-31https://findrochetrials.ca/en/trials/autoimmune-disorder/jia/a-study-of-decreased-dose-frequency-in-participants-with-systemi.html2024-08-30https://findrochetrials.ca/en/trials/autoimmune-disorder/jia/a-study-of-subcutaneously--sc--administered-tocilizumab-80633.html2024-06-22https://findrochetrials.ca/en/trials/autoimmune-disorder/jia/a-study-of-subcutaneously-administered-tocilizumab-in-p-36947.html2024-06-22https://findrochetrials.ca/en/trials/autoimmune-disorder/ra.html2020-08-25https://findrochetrials.ca/en/trials/autoimmune-disorder/sjogren-s-syndrome.html2020-08-25https://findrochetrials.ca/en/trials/autoimmune-disorder/ulcerative-colitis/a-study-comparing-the-efficacy-and-safety-of-etrolizumab-to-infl.html2024-09-01https://findrochetrials.ca/en/trials/autoimmune-disorder/sle.html2020-08-25https://findrochetrials.ca/en/trials/autoimmune-disorder/ibd.html2020-08-25https://findrochetrials.ca/en/trials/autoimmune-disorder/gpa/a-phase-iia-study-of-intravenous-rituximab-in-pediatric-00800.html2024-06-21https://findrochetrials.ca/en/trials/autoimmune-disorder/a-study-to-evaluate-the-efficacy-and-safety-of-rituxima-33498.html2026-04-01https://findrochetrials.ca/en/trials/autoimmune-disorder/ln.html2020-08-25https://findrochetrials.ca/en/trials/autoimmune-disorder/neuromyelitis-optica-spectrum-disorders/efficacy-and-safety-study-of-satralizumab--sa237--as-mo-50688.html2024-09-01https://findrochetrials.ca/en/trials/autoimmune-disorder/pnh.html2020-08-25https://findrochetrials.ca/en/trials/autoimmune-disorder/a-clinical-trial-of-omalizumab-in-participants-with-chronic-rhin.html2024-08-30https://findrochetrials.ca/en/trials/autoimmune-disorder/an-extension-study-of-omalizumab-in-participants-with-chronic-rh.html2024-08-31https://findrochetrials.ca/en/trials/eye-disorder/dme/a-study-to-evaluate-the-efficacy-and-safety-of-ro686746-59371.html2024-08-31https://findrochetrials.ca/en/trials/eye-disorder/glaucoma.html2020-08-25https://findrochetrials.ca/en/trials/eye-disorder/amd/a-study-to-evaluate-the-safety--tolerability--pharmacok-30793.htmlhttps://findrochetrials.ca/en/trials/eye-disorder/amd/a-study-to-evaluate-the-long-term-safety-and-tolerabili-60381.htmlhttps://findrochetrials.ca/en/trials/eye-disorder/wamd/a-study-to-evaluate-the-efficacy-and-safety-of-faricima-34628.html2024-08-30https://findrochetrials.ca/en/trials/muscle-and-peripheral-nerve-disease/sma/a-study-to-investigate-the-safety--tolerability--pharmacokinetic1.html2024-08-31https://findrochetrials.ca/en/trials/muscle-and-peripheral-nerve-disease/dmd/clinical-trial-to-evaluate-the-efficacy--safety--and-to-14306.html2024-08-31https://findrochetrials.ca/en/trials/muscle-and-peripheral-nerve-disease/muscular-dystrophy/study-of-an-investigational-drug--ro7239361--bms-986089-96144.html2024-08-31https://findrochetrials.ca/en/trials/infectious-diseases/hbv.html2020-08-25https://findrochetrials.ca/en/trials/infectious-diseases/hbv/a-trial-to-evaluate-the-efficacy-and-safety-of-multiple-42976.htmlhttps://findrochetrials.ca/en/trials/infectious-diseases/influenza/study-to-assess-efficacy-and-safety-of-baloxavir-marbox-94137.html2024-09-01https://findrochetrials.ca/en/trials/infectious-diseases/bacterial-infection.html2020-08-25https://findrochetrials.ca/en/trials/infectious-diseases/efficacy-and-safety-of-gdc-0853-in-participants-with-refractory-.html2024-08-30https://findrochetrials.ca/en/trials/infectious-diseases/hcv.html2020-08-25https://findrochetrials.ca/en/trials/neurodegenerative-disorder/ad/a-study-of-crenezumab-versus-placebo-to-evaluate-the-efficacy-an.html2024-09-01https://findrochetrials.ca/en/trials/neurodegenerative-disorder/ad/a-study-to-evaluate-the-efficacy-and-safety-of-ro7105705-in-pati.html2024-08-31https://findrochetrials.ca/en/trials/neurodegenerative-disorder/ad/a-study-of-gantenerumab-in-participants-with-mild-alzhe-16675.html2024-06-22https://findrochetrials.ca/en/trials/neurodegenerative-disorder/ad/a-study-of-gantenerumab-in-participants-with-prodromal--48625.html2024-08-31https://findrochetrials.ca/en/trials/neurodegenerative-disorder/ad/a-study-to-evaluate-the-efficacy-and-safety-of-gantener-84528.html2024-08-30https://findrochetrials.ca/en/trials/neurodegenerative-disorder/ad/a-study-to-evaluate-the-safety-and-tolerability-of-long-88018.html2024-08-31https://findrochetrials.ca/en/trials/neurodegenerative-disorder/ad/cread-study--a-study-of-crenezumab-versus-placebo-to-ev-21662.html2024-08-31https://findrochetrials.ca/en/trials/neurodegenerative-disorder/ad/efficacy-and-safety-study-of-gantenerumab-in-participants-with-e.html2024-08-30https://findrochetrials.ca/en/trials/neurodegenerative-disorder/als/a-study-of-gdc-0134-to-determine-initial-safety--tolerability--a.html2024-08-31https://findrochetrials.ca/en/trials/neurodegenerative-disorder/pd.html2020-08-25https://findrochetrials.ca/en/trials/neurodegenerative-disorder/multiple-sclerosis/study-to-evaluate-the-effectiveness-and-safety-of-ocrelizumab-in.html2025-01-16https://findrochetrials.ca/en/trials/neurodegenerative-disorder/multiple-sclerosis/a-study-to-evaluate-ocrelizumab-treatment-in-participants-with-p.html2025-03-27https://findrochetrials.ca/en/trials/neurodegenerative-disorder/multiple-sclerosis/study-to-explore-the-mechanism-of-action-of-ocrelizumab-and-b-ce.html2024-08-31https://findrochetrials.ca/en/trials/neurodegenerative-disorder/multiple-sclerosis/a-study-to-evaluate-the-effects-of-ocrelizumab-on-immun-95763.html2026-04-01https://findrochetrials.ca/en/trials/neurodegenerative-disorder/multiple-sclerosis/a-study-to-evaluate-the-efficacy--safety-and-pharmacoki-18428.html2025-03-27https://findrochetrials.ca/en/trials/neurodegenerative-disorder/multiple-sclerosis/a-study-of-ocrelizumab-in-participants-with-primary-pro-36628.htmlhttps://findrochetrials.ca/en/trials/neurodegenerative-disorder/multiple-sclerosis/a-rollover-study-to-evaluate-the-long-term-safety-and-e-52490.html2025-03-27https://findrochetrials.ca/en/trials/neurodegenerative-disorder/hd/study-to-measure-cerebrospinal-fluid-mutant-huntingtin--30045.html2025-01-04https://findrochetrials.ca/en/trials/neurodegenerative-disorder/hd/study-in-huntington-s-disease-patients-who-participated-34698.html2024-08-30https://findrochetrials.ca/en/trials/neurodevelopmental-disorder/autism/a-12-week-placebo-controlled-study-to-investigate-the-e-88629.html2025-01-29https://findrochetrials.ca/en/trials/neurodevelopmental-disorder/angelman-syndrome.html2020-08-25https://findrochetrials.ca/en/trials/psychiatric-disorder.html2020-08-25https://findrochetrials.ca/en/trials/psychiatric-disorder/schizophrenia.html2020-08-25https://findrochetrials.ca/en/trials/respiratory-disorder/ipf/a-study-to-characterize-the-disease-behavior-of-idiopathic-pulmo.html2024-08-30https://findrochetrials.ca/en/trials/respiratory-disorder/ipf/efficacy--safety--and-tolerability-study-of-pirfenidone-in-combi.html2026-03-26https://findrochetrials.ca/en/trials/respiratory-disorder/asthma/a-study-to-assess-the-efficacy-and-safety-of-mstt1041a--35784.html2024-06-21https://findrochetrials.ca/en/trials/respiratory-disorder/copd.html2020-08-25https://findrochetrials.ca/en/trials/respiratory-disorder/copd/a-study-of---_xe-mri-to-assess-disease-progression-in-p-99725.htmlhttps://findrochetrials.ca/en/trials/healthy-volunteers.html2020-08-25https://findrochetrials.ca/en/trials/kidney-disorder.html2020-08-25https://findrochetrials.ca/en/trials/kidney-disorder/ckd.html2020-08-25https://findrochetrials.ca/en/trials/kidney-disorder/renal-failure.html2020-08-25https://findrochetrials.ca/en/trials/metabolic-disorder/t1d.html2020-08-25https://findrochetrials.ca/en/trials/metabolic-disorder/t2d/a-multiple-ascending-dose-study-to-evaluate-safety-and-tolerabil.html2024-08-31https://findrochetrials.ca/en/trials/metabolic-disorder/Liver_Failure.html2020-08-25https://findrochetrials.ca/en/trials/metabolic-disorder/hepatic-insufficiency.html2020-08-25https://findrochetrials.ca/en/trials/metabolic-disorder/dr.html2020-08-25https://findrochetrials.ca/en/trials/metabolic-disorder/lysosomal-storage-diseases.html2020-08-25https://findrochetrials.ca/en/trials/cardiovascular-disorder.html2020-08-25https://findrochetrials.ca/en/trials/cardiovascular-disorder/AIS.html2020-08-25https://findrochetrials.ca/en/trials/cardiovascular-disorder/AIS/tenecteplase-in-stroke-patients-between-4-and-24-hours-11566.htmlhttps://findrochetrials.ca/en/trials/hematologic-diseases/a-study-evaluating-the-efficacy--safety--pharmacokineti-29406.html2025-03-27https://findrochetrials.ca/en/trials/hematologic-diseases/myelodysplastic-syndrome.html2020-08-25https://findrochetrials.ca/en/trials/hematologic-diseases/Hemophilia/hemophilia-a/a-study-to-evaluate-the-safety-and-tolerability-of-prophylactic-.html2023-03-29https://findrochetrials.ca/en/faq.html2021-05-26https://findrochetrials.ca/en/faq/what-is-a-clinical-trial.html2023-05-09https://findrochetrials.ca/en/faq/why-should-i-consider-taking-part-in-a-clinical-trial.html2020-08-25https://findrochetrials.ca/en/faq/roche-in-clinical-trials.html2023-05-09https://findrochetrials.ca/en/error.html2020-08-25https://findrochetrials.ca/en/error/404.html2024-11-11https://findrochetrials.ca/en/error/403.html2024-11-11https://findrochetrials.ca/en/error/500.html2024-11-11https://findrochetrials.ca/en/privacy-policy.html2021-02-16https://findrochetrials.ca/en/About.html2020-08-25https://findrochetrials.ca/en/sitemap.html2020-08-25https://findrochetrials.ca/en/covid-19.html2021-04-26https://findrochetrials.ca/en/disease-area-overview.html2020-08-25https://findrochetrials.ca/en/terms-and-conditions.html2021-02-16https://findrochetrials.ca/en/faq1.html2023-05-09https://findrochetrials.ca/en/faq1/what-is-a-clinical-trial.html2023-05-09https://findrochetrials.ca/en/faq1/why-should-i-consider-taking-part-in-a-clinical-trial.html2022-11-22https://findrochetrials.ca/en/faq1/roche-in-clinical-trials.html2023-05-09https://findrochetrials.ca/en/faq1/advancing-inclusive-research.html2022-11-22https://findrochetrials.ca/en/faq1/what-is-an-observational-trial.html2022-11-22https://findrochetrials.ca/en/new-solr-search.html2024-02-27